Nachrichten zur BioCryst Pharmaceuticals Inc. Aktie

BioCryst wins Canadian nod for Orladeyo reimbursement

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Shares of BioCryst Pharmaceuticals Jumped Today

A day after the stock plummeted, it bounced back....…

BioCryst adds 13% to rebound as Needham upgrades; says selloff overdone

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Opening Bell: Nasdaq 100, Dow Jones, Walmart, Palo Alto, Palantir, Coinbase, JD.com, PDD, BioCryst

Die Wall Street startete erst gestern in die neue Handelswoche. Und es war ein verhaltener Start. Der Dow Jones gab…

Opening Bell: Wall Street startet nach Vortagesverlusten freundlich; Fed-Protokoll, Walmart, JD.com, Palo Alto Networks, Palantir, Biocryst, PDD Holdings im Fokus

Die US-Börsen dürften am Mittwoch einen Stabilisierungsversuch starten. Der Dow Jones notiert 30 Minuten vor dem Handelsstart bei 33.182 Punkten,…

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst Pharmaceuticals Stock Down 20% After Wider 4Q Loss Reported

BioCryst Pharmaceuticals Stock Down 20% After Wider 4Q Loss Reported...…

Why BioCryst Pharmaceuticals Stock Is Sinking Today

Investors didnt like the drugmakers Q4 update....…

BioCryst Pharmaceuticals (BCRX) Q4 2022 Earnings Call Transcript

BCRX earnings call for the period ending December 31, 2022....…

BioCryst at nine-month low as Q4 bottom-line disappoints

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -100% and 6.11%, respectively, for the quarter ended December 2022. Do the…

Form 8-K BIOCRYST PHARMACEUTICALS For: Feb 21

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Pharmaceuticals Q4 2022 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Opening Bell: TripAdvisor, Airbnb, Tesla, Biogen, BioCryst

Die US-Inflationsdaten sorgten gestern für eine kleine Berg- und Talfahrt bei den US-Indizes. Am Ende ging der Dow Jones mit…

Opening Bell: Dow Jones startet im Minus; Einzelhandelsumsätze Januar, Biogen, Tripadvisor, Airbnb, Tesla, Biocryst im Fokus

Starke Einzelhandelsumsätze im Januar verunsichern am Mittwoch die Anleger an der Wall Street und drücken die Indizes ins Minus. 30…

BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

Insiderhandel: President & CEO verkauft Aktien von BioCryst Pharmaceuticals im Wert von 1.038.000$

Stonehouse, Jon P. - Vorstand - Tag der Transaktion: 2023-02-01...…

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment…

BioCryst teams up with Swixx to sell Orladeyo in Central, Eastern Europe

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company…

BioCryst drops as sales for hereditary angioedema therapy lag forecasts

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Shares Down After Orladeyo Preliminary Sales, Outlook

BioCryst Shares Down After Orladeyo Preliminary Sales, Outlook...…

Form 8-K BIOCRYST PHARMACEUTICALS For: Jan 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

—ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)—...…

BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

Insiderhandel: Exec. Director, Finance - PAO verkauft Aktien von BioCryst Pharmaceuticals im Wert von 4.851$

Jones, Michael L. - Vorstand - Tag der Transaktion: 2022-12-15...…

Insiderhandel: Chief Legal Officer verkauft Aktien von BioCryst Pharmaceuticals im Wert von 45.424$

Barnes, Alane P. - Vorstand - Tag der Transaktion: 2022-12-15...…

BioCryst (BCRX) Down as it Discontinues Developing PNH Drug

BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH....…

BioCryst strategic interest likely to rise after oral Factor D inhibitor decision - Cowen

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst to discontinue development of drug

Shares of BioCryst Pharmaceuticals Inc. were down about 5% in premarket trading on Thursday after the company said it…

BioCryst Shares Fall Premarket After BCX9930 Program Scrapped >BCRX

BioCryst Shares Fall Premarket After BCX9930 Program Scrapped >BCRX...…

Form 8-K BIOCRYST PHARMACEUTICALS For: Dec 15

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst to Present at JMP Securities Hematology & Oncology Summit

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

Insiderhandel: President & CEO verkauft Aktien von BioCryst Pharmaceuticals im Wert von 1.057.997$

Stonehouse, Jon P. - Vorstand - Tag der Transaktion: 2022-12-02...…

Insiderhandel: Exec. Director, Finance - PAO verkauft Aktien von BioCryst Pharmaceuticals im Wert von 111.886$

Jones, Michael L. - Vorstand - Tag der Transaktion: 2022-12-01...…

Insiderhandel: President & CEO verkauft Aktien von BioCryst Pharmaceuticals im Wert von 2.793.921$

Stonehouse, Jon P. - Vorstand - Tag der Transaktion: 2022-12-01...…

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health

RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world…

Form 10-Q BIOCRYST PHARMACEUTICALS For: Sep 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

4 Analysts Have This to Say About BioCryst Pharmaceuticals

Within the last quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) has observed the following analyst ratings: Latest Ratings for BCRX …

BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript

BCRX earnings call for the period ending September 30, 2022....…

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of 28.13% and 3.23%, respectively, for the quarter ended September 2022. Do the…

BioCryst Pharmaceuticals Q3 2022 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

dpa-AFX ProFeed